

Table S2

Characteristic	cluster 1:lower-intake/sugar-enriched N = 114 <sup>1</sup>	cluster2:higher-intake N = 59 <sup>1</sup>	p-value <sup>2</sup>
Age	60 (14)	62 (18)	0.4
Sex			<0.001
Male	50 (44%)	45 (76%)	
Female	64 (56%)	14 (24%)	
Disease			0.040
Acute myeloid leukemia	47 (41%)	21 (36%)	
MDS/MPN	38 (33%)	19 (32%)	
Non-Hodgkin's lymphoma	6 (5.3%)	11 (19%)	
Acute lymphoid leukemia	11 (9.6%)	1 (1.7%)	
Other	7 (6.1%)	4 (6.8%)	
Myeloma	4 (3.5%)	1 (1.7%)	
Chronic lymphocytic leukemia	1 (0.9%)	2 (3.4%)	
Graft type			0.002
Unmodified bone marrow or PBSC	47 (41%)	41 (69%)	
T-cell depleted PBSC	57 (50%)	15 (25%)	
Cord blood	10 (8.8%)	3 (5.1%)	
Intensity of conditioning regimen			<0.001
Ablative	71 (62%)	29 (49%)	
Reduced intensity	39 (34%)	13 (22%)	
Nonmyeloablative	4 (3.5%)	17 (29%)	
GvHD prophylaxis			0.004
CNI-based	36 (32%)	23 (39%)	
PTCy-based	21 (18%)	21 (36%)	
T-cell depleted PBSC	57 (50%)	15 (25%)	
Days exposed to broad-spectrum antibiotics	9.0 (11.0)	3.0 (12.0)	0.018

<sup>1</sup> Median (IQR); n (%)

<sup>2</sup> Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test